CA Patent

CA2325201A1 — Methods of administering apo b-secretion/mtp inhibitors

Assigned to Pfizer Products Inc · Expires 2001-05-10 · 25y expired

What this patent protects

Disclosed is a medicine for reducing total serum cholesterol and LDL-cholesterol, which comprises (a) a pharmaceutically acceptable carrier, vehicle or diluent and (b) an effective amount of an apolipoprotein B-secretion (apo B)/microsomal triglyceride transfer protein (MTP) inhi…

USPTO Abstract

Disclosed is a medicine for reducing total serum cholesterol and LDL-cholesterol, which comprises (a) a pharmaceutically acceptable carrier, vehicle or diluent and (b) an effective amount of an apolipoprotein B-secretion (apo B)/microsomal triglyceride transfer protein (MTP) inhibitor and which is to be taken by a subject in need of such reduction prior to or during a somnolent period of the subject being treated.

Drugs covered by this patent

Patent Metadata

Patent number
CA2325201A1
Jurisdiction
CA
Classification
—
Expires
2001-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Products Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.